Fujifilm’s owns iPS cell technology and sophisticated engineering technology c through its US subsidiary, Cellular Dynamics International, and Takeda Pharmaceutical does joint research (T – CiRA) with Kyoto University iPS cell research institute (CiRA). Both companies will jointly develop and commercialize regenerative medical products using iPS cell derived cardiomyocytes.

Fujifilm news release, February 8, 2018